Clinical trial

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-01-26

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2026-01-26Date precision: day

Registry last updated2026-09-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Melanoma (Skin Cancer)unresolved

HER2-low Hormone Receptor Positive Breast Cancerunresolved

Interventions

AMXT 1501 DicaprateDRUG

DFMODRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

CapivasertibDRUG · verified · RxNorm: capivasertib

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Aminex Therapeutics, Inc.lead sponsor

Mapped research locations

HoustonTexas, United States2 NashvilleTennessee, United States2 Los AngelesCalifornia, United States1 DallasTexas, United States1 San FranciscoCalifornia, United States1 CincinnatiOhio, United States1 DetroitMichigan, United States1 AustinTexas, United States1 TucsonArizona, United States1 La JollaCalifornia, United States1 MadisonWisconsin, United States1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07287917 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.